During Q4 2018 the big money sentiment decreased to 1. That’s change of 0.15, from 2018Q3’s 1.15. 23 investors sold all, 15 reduced holdings as Sorrento Therapeutics, Inc. ratio turned negative. 28 rose stakes while 10 funds bought stakes. Funds hold 30.19 million shares thus 3.21% less from 2018Q3’s 31.19 million shares.
Matrix Asset holds 60,000 shs. Wildcat Capital Management Limited Company owns 0.66% invested in Sorrento Therapeutics, Inc. (NASDAQ:SRNE) for 415,765 shs. Tci Wealth Advsrs reported 200 shs. Voya Invest Limited Liability Com stated it has 0% of its capital in Sorrento Therapeutics, Inc. (NASDAQ:SRNE). Blackrock holds 7.57M shs. Ny State Common Retirement Fund stated it has 93,700 shs. State Of Wisconsin Investment Board owns 113,000 shs. Sigma Planning has invested 0% in Sorrento Therapeutics, Inc. (NASDAQ:SRNE). Tiaa Cref Invest Limited Liability Company has invested 0% in Sorrento Therapeutics, Inc. (NASDAQ:SRNE). Alpine Mngmt Limited owns 148,195 shs for 0.09% of their capital. Goldman Sachs Gru owns 125,720 shs for 0% of their capital. Ameritas Inv Partners holds 7,245 shs. Weiss Asset Limited Partnership owns 26,420 shs. Illinois-based Ubs Asset Americas has invested 0% in Sorrento Therapeutics, Inc. (NASDAQ:SRNE). Jefferies Grp Limited Company stated it has 0% of its capital in Sorrento Therapeutics, Inc. (NASDAQ:SRNE).
Sorrento Therapeutics Inc (NASDAQ:SRNE) had a decrease of its short interest by 4.91%. In March was published SRNE’s total 19.08M short interest by FINRA. That’s 4.91% down from 20.06 million shares. With Average volume 1.24 million, SRNE’s former position will take 15 days to recover. Sorrento Therapeutics Inc’s short interest float is 30.24%.
Ticker’s shares touched $4.71 during the last trading session after 8.37% change.Sorrento Therapeutics, Inc. is downtrending after having declined 72.85% since March 27, 2018. SRNE has 7.76M volume or 192.76% up from normal. SRNE underperformed by 77.22% the S&P500.
Sorrento Therapeutics, Inc., a clinical stage biotechnology company, primarily engages in the discovery and development of therapies focused on oncology and the treatment of chronic cancer pain worldwide.The firm is worth $540.29 million. It develops therapeutic products for the treatment of auto-immune, inflammatory, neurodegenerative, and infectious diseases.Currently it has negative earnings. The firm offers resiniferatoxin, a non-opioid TRPV1 agonist neurotoxin for the treatment of intractable pain at end-stage disease.
Sorrento Therapeutics, Inc. (NASDAQ:SRNE) Ratings Coverage
In total 2 analysts cover Sorrento Therapeutics (NASDAQ:SRNE). “Buy” rating has 2, “Sell” are 0, while 0 are “Hold”. (NASDAQ:SRNE) has 100% bullish analysts. 2 are the (NASDAQ:SRNE)’s ratings reports on Mar 27, 2019 according to StockzIntelligence Inc. On Wednesday, March 20 FBR Capital maintained Sorrento Therapeutics, Inc. (NASDAQ:SRNE) rating. FBR Capital has “Buy” rating and $12 target. On Friday, March 22 the company was maintained by H.C. Wainwright.
For more Sorrento Therapeutics, Inc. (NASDAQ:SRNE) news brought out recently go to: Nasdaq.com, Nasdaq.com, Benzinga.com, Nasdaq.com or Seekingalpha.com. The titles are as follows: “Mid-Day Market Update: Superconductor Technologies Rises After Q4 Results; Staffing 360 Solutions Shares Slide – Nasdaq” brought out on March 21, 2019, “Mid-Morning Market Update: Markets Open Lower; Hibbett Sports Beats Q4 Estimates – Nasdaq” on March 22, 2019, “60 Stocks Moving In Wednesday’s Mid-Day Session – Benzinga” with a publish date: March 27, 2019, “Mid-Afternoon Market Update: U.S. Stocks Turn Lower; Blucora Shares Spike Higher – Nasdaq” and the last “Sorrento Therapeutics and Altimmune among healthcare gainers; Selecta Biosciences and AquaBounty Technologies among losers – Seeking Alpha” with publication date: March 19, 2019.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.